Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virological evidence of HPV infection
| Autor: | Teresa M. Hesley, Mauricio Hernández-Ávila, Luisa L. Villa, Daron G. Ferris, Annemarie R. Thornton, Nubia Muñoz, Margaret James, Laura A. Koutsky, Radha Railkar, Robert J. Kurman, Steinar Thoresen, Carlos Sattler, Gonzalo Perez, Evan R. Myers, Hseon Tay Eng, Eliav Barr, Susanne K. Kjaer, Mark T. Esser, Kevin A. Ault, Patricia J. Garcia, Kristjan Sigurdsson, Darron R. Brown, Ole Eric Iversen, Janine T. Bryan, Scott Vuocolo, Sven Eric Olsson, Joakim Dillner, Micki Nelson, Slawomir Majewski, Matti Lehtinen, Jorma Paavonen, John W. Boslego, F. Xavier Bosch, Frank J. Taddeo |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
Adult
medicine.medical_specialty Adolescent Population Uterine Cervical Neoplasms Enzyme-Linked Immunosorbent Assay Disease Cervical intraepithelial neoplasia Antibodies Viral Injections Intramuscular Polymerase Chain Reaction 03 medical and health sciences 0302 clinical medicine Double-Blind Method Internal medicine medicine Immunology and Allergy Humans 030212 general & internal medicine Papillomavirus Vaccines Prospective Studies Human papillomavirus education Papillomaviridae education.field_of_study Hpv types business.industry Papillomavirus Infections HPV infection virus diseases Sexually Transmitted Diseases Viral medicine.disease Uterine Cervical Dysplasia female genital diseases and pregnancy complications Confidence interval 3. Good health Vaccination Infectious Diseases Treatment Outcome 030220 oncology & carcinogenesis DNA Viral Female business |
| Zdroj: | The Journal of infectious diseases. 196(10) |
| ISSN: | 0022-1899 |
| Popis: | Background. A quadrivalent (types 6, 11, 16, and 18) human papillomavirus (HPV) L1 virus-like-particle (VLP) vaccine has been shown to be 95%-100% effective in preventing cervical and genital disease related to HPV-6,-11,-16, and-18 in 16-26-year-old women naive for HPV vaccine types. Because most women in the general population are sexually active, some will have already been infected with >= 1 HPV vaccine types at the time vaccination is offered. Here, we assessed whether such infected women are protected against disease caused by the remaining HPV vaccine types. Methods. Two randomized, placebo-controlled trials of the quadrivalent (types 6, 11, 16, and 18) HPV vaccine enrolled 17,622 women without consideration of baseline HPV status. Among women infected with 1-3 HPV vaccine types at enrollment, efficacy against genital disease related to the HPV vaccine type or types for which subjects were naive was assessed. Results. Vaccination was 100% effective (95% confidence interval [CI], 79%-100%) in preventing incident cervical intraepithelial neoplasia 2 or 3 or cervical adenocarcinoma in situ caused by the HPV type or types for which the women were negative at enrollment. Efficacy for preventing vulvar or vaginal HPV-related lesions was 94% (95% CI, 81%-99%). Conclusions. Among women positive for 1-3 HPV vaccine types before vaccination, the quadrivalent HPV vaccine protected against neoplasia caused by the remaining types. These results support vaccination of the general population without prescreening. (Less) |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|